Beyond 4 weeks: Tirzepatide is considered completely cleared from your system
Many people dont say my mouth is dry. They say food sticks, their breath seems off, or they wake up feeling parched even after drinking water before bed
Key Findings 1 Tirzepatide reduced major kidney events by 23% vs dulaglutide Events: 6.0% vs 7.6% HR 0.77 (95% CI 0.680.88), p=0.0002 The risk of the primary composite kidney outcomewas 23% lower with tirzepatide than with dulaglutide. 2 Benefits were consistent across CKD risk categories Lowtomoderate risk CKD: HR 0.70 Highrisk CKD: HR 0.79 3 Mechanistic drivers differed by CKD stage Lowtomoderate CKD: Less newonset macroalbuminuria Highrisk CKD: Slower eGFR decline This was primarily driven by a lower rate of new-onset persistent macroalbuminuria and a lower rate of eGFR decline. 4 eGFR decline was significantly slower with tirzepatide Overall difference: +0.29 mL/min/1.73 m per year Highrisk CKD: +0.93 mL/min/1.73 m per year 5 Albuminuria improved more with tirzepatide At 36 months, UACR reductions were greater across CKD categories
Excited to continue with my orders from Citizen Meds
In separate Phase 2 and Phase 3 trials, retatrutide at 12mg produced greater total body weight reduction than semaglutide at 2.4mg across comparable timeframes, with the difference primarily attributable to retatrutides additional glucagon receptor activation
Intriguingly, TZP therapy has been postulated to exhibit reduced aversive and gastrointestinal side effects in part due to central antiaversive actions of GIP (42)